Verdict card (component)
⊘ Insufficient evidence
A heptapeptide derived from ACTH(4-10), developed at the Russian Academy of Sciences, approved in Russia for ischemic stroke and cognitive disorders. Like Selank, the evidence base is concentrated in Russian-language clinical literature with limited Western replication. The molecule is plausibly active — it’s structurally related to a real CNS-active peptide fragment — but the body-of-evidence required to recommend it for the cognitive-enhancement and longevity claims promoted in some communities does not exist.
Evidence signal row
- ! Russian clinical use — approved for ischemic stroke and cognitive disorders
- ! No Western RCT replication of cognitive-enhancement claims
- ⊘ Mechanism partially characterized — neuroprotective and BDNF-modulating effects in animal models
Our verdict (4 sentences)
Semax is the third member of the Russian peptide trio (with Epitalon and Selank) that we cover in v1, and the same verdict logic applies: real Russian-clinical evidence, real mechanistic plausibility, no Western replication. The ACTH(4-10) backbone is biologically active and well-characterized — these are the residues responsible for the behavioral and CNS effects of ACTH that don’t depend on adrenal stimulation. Whether Semax produces the cognitive-enhancement effects users seek, at the doses and durations used outside Russian clinical practice, is uncharacterized. Insufficient evidence honestly: it likely does something, but what it reliably does in non-clinical-indication populations is not the question Russian research has answered.
Mechanism
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Structurally, it is a modified version of ACTH residues 4-7 (Met-Glu-His-Phe) extended with a stabilizing Pro-Gly-Pro tail.
The ACTH(4-10) fragment is biologically interesting: it contains the residues responsible for the behavioral, attention, and memory effects of full-length ACTH, without containing the residues responsible for adrenal stimulation. ACTH(4-10) and related fragments have been studied since the 1970s as potential cognitive-enhancement and neuroprotective agents.
The proposed mechanisms (multiple, partially characterized):
- BDNF (brain-derived neurotrophic factor) modulation — Semax administration has been shown to increase BDNF expression in animal hippocampus, with downstream effects on synaptic plasticity and neuroprotection
- Anti-apoptotic effects in neurons under ischemic stress
- Modulation of dopaminergic and serotonergic neurotransmission
- Anti-inflammatory effects in CNS
- Melanocortin receptor activity — the ACTH structural relationship implies some MC receptor binding, though specificity for which MC receptor at therapeutic doses is debated
The standard route in Russian clinical use is intranasal spray. A short peptide with this structure has reasonable nasal-mucosa absorption and CNS access via the olfactory pathway; first-pass metabolism via oral or peripheral routes would degrade much of the dose.
Half-life is short (estimated 15–30 minutes in plasma) but CNS effects appear to outlast plasma exposure.
What the evidence shows
Russian clinical research base (substantial):
- Acute ischemic stroke — multiple trials showing improvements in neurological recovery scales when Semax is added to standard care; this is the primary approved indication
- Cognitive disorders (vascular dementia, mild cognitive impairment) — trials showing modest improvements in cognitive scales
- Attention disorders in children — some trials, mixed results
- Psychosomatic and asthenic conditions — additional smaller bodies of work
Western evidence:
- A few mechanistic studies (some in collaboration with Russian groups) on BDNF effects and neuroprotection
- No Western RCTs at pharmaceutical-development standards
- No replication of the stroke-recovery clinical findings in non-Russian patient populations
The mechanistic case is stronger than the clinical-replication case:
The BDNF-modulating effects, anti-apoptotic effects, and ACTH(4-10)-related neurobehavioral effects are real findings supported by multiple labs. What’s missing is the bridge from “this peptide modulates BDNF in rat hippocampus” to “this peptide produces measurable cognitive enhancement in healthy human users at gray-market doses.” That bridge is not in the published literature.
Dosing literature
Russian clinical use (intranasal):
- 0.1% or 1% solution intranasal, 2–4 drops per nostril (~200–600 mcg), 2–3 times daily
- Course duration 10–14 days for acute conditions, longer for chronic indications
Gray-market protocols (Western contexts):
- Generally similar intranasal doses
- Some subcutaneous protocols exist but bioavailability and CNS penetration are different
The intranasal route is the route the Russian evidence is based on. Subcutaneous protocols sold by gray-market vendors are not equivalent.
Risks and adverse events
In Russian clinical reports:
- Generally well-tolerated acute profile
- Mild local irritation with intranasal administration
- Occasional headache or transient stimulation
- No significant CNS depression or sedation
Theoretical concerns:
- Long-term effects on BDNF and neurotrophin systems are not characterized in chronic-use contexts
- Effects on cortisol and HPA-axis — the ACTH structural relationship raises questions about whether chronic Semax exposure has any HPA-axis effects, even though the truncated structure is supposed to lack adrenal stimulation. Russian clinical use has not surfaced major endocrine concerns; long-term exposure outside that clinical context is uncharacterized.
- Drug interactions with antidepressants, stimulants, or other CNS-active agents are not characterized in detail.
Quality concerns:
Same as Selank — short heptapeptide, easy to synthesize, gray-market product quality varies, intranasal formulations are sometimes mis-prepared.
Regulatory status
| Region | Status | Notes |
|---|---|---|
| United States | Not approved | |
| European Union | Not approved | |
| United Kingdom | Not approved | |
| Russia | Approved | For ischemic stroke (acute and recovery), encephalopathy, transient ischemic attack, cognitive disorders. On the Russian List of Vital & Essential Drugs (formally added December 7, 2011) — incorporated into Russian national stroke-management clinical guidelines. |
| Some Eastern European markets | Approved or recognized | Variable. |
| Most other markets | Not approved |
Where to get it
We do not route readers to a fulfillment partner for Semax. The Insufficient evidence verdict reflects honest uncertainty about effects in non-Russian-clinical-context use.
For readers in Russia or in clinical relationships with practitioners familiar with the Russian peptide pharmacopeia, the legitimate access path is prescription for an approved indication. For Western users seeking cognitive enhancement, the gray-market is the practical-but-not-recommended path.
(See How we make money.)
References (selected)
- Gusev EI et al. Neuroprotective effects of Semax in acute ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2005.
- Dolotov OV et al. Semax, an analogue of ACTH(4-10), regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006. PubMed
- Inozemtseva LS et al. Intracerebroventricular administration of the neuroprotective peptide Semax protects against the development of post-traumatic stress disorder in rats. Med Sci Monit Basic Res 2012.
- Medvedeva EV et al. Effects of t
Quick Facts
| Also Known As | ACTH(4-7)-Pro-Gly-Pro, ACTH(4-10) analog, Heptapeptide Semax |
|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Molecular Formula | C37H51N9O10S |
| Molecular Weight | 813.9 Da |
| PubChem CID | 9811102 |
Research Parameters
| Half-Life | Approximately 30-40 minutes in plasma, but its central effects persist for several hours due to active metabolites and triggered genomic mechanisms. |
|---|---|
| Stability | Lyophilized powder is stable for at least 24 months when stored at -20°C, protected from light and moisture. After reconstitution in sterile water or saline, the solution is typically stable for 7-14 days when stored at 2-8°C (refrigerated). |
| Solubility | Sterile Water for Injection, 0.9% Sodium Chloride (normal saline). Bacteriostatic Water may also be used for research purposes. |
| Vial Size | 3 mg |
| Storage (Lyophilized) | -20°C or below, protected from light and moisture. Desiccated. |
| Storage (Reconstituted) | 2-8°C (refrigerated) for up to 14 days. Protect from light. Do not freeze. |
| Typical Research Dose | In research, doses often range from 200 mcg to 800 mcg per day for a human-equivalent model, administered intranasally. Animal study doses vary widely (e.g., 50-300 mcg/kg). |
| Cycle Parameters | Research protocols often involve daily intranasal administration for periods of 10 to 14 days, sometimes repeated after a break. Chronic studies have used continuous administration for several weeks. |
| Amino Acid Count | 7 |
Mechanism of Action
Semax exerts its primary effects through modulation of neurotrophic factors and neurotransmitter systems, without stimulating the adrenal cortex. Its mechanism is multifaceted, involving both rapid neurotransmitter effects and longer-term genomic influences on neuroplasticity.
BDNF/TrkB Pathway Activation: Semax upregulates the expression of Brain-Derived Neurotrophic Factor (BDNF) and its receptor, TrkB. This activation promotes neuronal survival, enhances synaptic plasticity, and supports long-term potentiation (LTP), a cellular correlate of learning and memory.
Dopaminergic and Serotonergic Modulation: The peptide influences the metabolism of key neurotransmitters. It increases the brain levels of dopamine and serotonin, while also affecting their turnover. This modulation is associated with its positive effects on mood, motivation, and cognitive function.
Opioid System Interaction: Semax interacts with the endogenous opioid system, potentially through non-opioid mechanisms or via specific binding sites. This interaction is thought to contribute to its analgesic and stress-protective properties, without developing classical opioid tolerance or dependence.
Anti-Excitotoxic and Antioxidant Effects: It demonstrates protective effects against glutamate-induced excitotoxicity, a common pathway in neuronal injury. Semax also enhances the activity of endogenous antioxidant systems, reducing oxidative stress in neural tissues.
Regulation of Gene Expression: Semax influences the expression of genes related to neuroprotection, synaptic function, and stress response, including early-response genes like c-fos, contributing to its adaptive and protective roles.
Research Applications
Neuroprotection and Stroke Recovery: Research indicates Semax reduces infarct volume and improves functional outcomes in models of ischemic stroke. It promotes neuronal survival, reduces edema, and enhances recovery of neurological functions, potentially by modulating BDNF and reducing excitotoxicity.
Cognitive Enhancement and Nootropic Effects: Studies demonstrate its ability to improve learning, memory consolidation, and attention in various animal models and human trials. It is investigated for conditions involving cognitive decline, with effects linked to increased BDNF and improved cholinergic transmission.
Anxiety and Stress Resilience: Semax exhibits pronounced anxiolytic and adaptogenic properties in preclinical studies. It helps normalize behavior and physiological parameters under stress conditions, potentially via modulation of the HPA axis reactivity and monoaminergic systems.
Optic Nerve and Retinal Disorders: Applied research explores its efficacy in treating optic nerve atrophy, glaucoma, and other retinal pathologies. Its neurotrophic effects are believed to support the survival of retinal ganglion cells and improve visual function.
Psychiatric Disorders: Preliminary research explores its potential as an adjunct in treating depression and PTSD, linked to its effects on monoamine neurotransmission, BDNF, and stress hormone regulation.
Safety & Side Effects
Based on extensive clinical use in Russia and published studies, Semax has a favorable safety profile with low toxicity. No serious adverse events have been reported in clinical trials. Anecdotally reported side effects are rare and mild, primarily local irritation at the administration site (nasal mucosa) such as slight burning or sneezing immediately after instillation. No systemic side effects typical of corticosteroids are observed due to its lack of adrenal-stimulating activity. Theoretical concerns, based on its mechanism, are minimal but could include theoretical interactions with other CNS-active drugs. Long-term safety data beyond several months of use are limited.
Dosage Information
This information is derived from published research and clinical studies, primarily from Russia where it is a registered drug. It is presented for research and educational purposes only.
In human clinical studies, Semax is typically administered as a 0.1% or 1% solution intranasally. Common research doses range from 50 mcg/kg to 300 mcg/kg per day, though standard clinical doses are often in the range of 200-800 mcg per day for an adult, divided into 2-3 intranasal instillations. The primary route of administration in research is intranasal, allowing direct delivery to the CNS via the olfactory and trigeminal pathways. Subcutaneous injection has also been used in some animal studies. Treatment duration in studies varies from acute (single dose) to chronic administration over several weeks (e.g., 10-14 days is common in clinical trials for stroke or cognitive impairment).
References
Ashmarin, I.P., et al. 'Two newly discovered regulatory peptides: Semax and Selank.' Neuroscience and Behavioral Physiology, vol. 28, no. 1, 1998, pp. 23-27.
Dolotov, O.V., et al. 'Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.' Brain Research, vol. 1117, no. 1, 2006, pp. 54-60.
Gusev, E.I., et al. 'Semax in the treatment of patients with acute ischemic stroke.' Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, vol. 97, no. 10, 1997, pp. 35-39.
Kaplan, A.Ya., et al. 'The nootropic peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain: a transcriptome analysis.' BMC Genomics, vol. 21, no. 1, 2020, p. 468.
Levitskaya, N.G., et al. 'Effects of Semax on the BDNF content in rat hippocampus and frontal cortex.' Bulletin of Experimental Biology and Medicine, vol. 141, no. 5, 2006, pp. 600-602.
Medvedev, A.E., et al. 'Mechanisms of neuroprotective and nootropic action of Semax.' Eksperimental'naia i Klinicheskaia Farmakologiia, vol. 67, no. 5, 2004, pp. 71-78.
Zolotarev, Yu.A., et al. 'Synthesis and investigation of the ACTH(4-10) analog Semax.' Russian Journal of Bioorganic Chemistry, vol. 20, no. 12, 1994, pp. 1315-1322.